BeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. trimmed its position in shares of BeiGene, Ltd. (NASDAQ:BGNEGet Rating) by 93.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 145 shares of the company’s stock after selling 2,076 shares during the period. Daiwa Securities Group Inc.’s holdings in BeiGene were worth $27,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Pinebridge Investments L.P. acquired a new position in BeiGene during the 4th quarter valued at about $27,000. Koshinski Asset Management Inc. boosted its stake in BeiGene by 139.6% during the 1st quarter. Koshinski Asset Management Inc. now owns 242 shares of the company’s stock valued at $46,000 after purchasing an additional 141 shares during the period. Laurel Wealth Advisors Inc. acquired a new position in BeiGene during the 4th quarter valued at about $249,000. Blair William & Co. IL boosted its stake in BeiGene by 44.4% during the 4th quarter. Blair William & Co. IL now owns 1,083 shares of the company’s stock valued at $293,000 after purchasing an additional 333 shares during the period. Finally, Vestmark Advisory Solutions Inc. boosted its stake in BeiGene by 27.1% during the 1st quarter. Vestmark Advisory Solutions Inc. now owns 1,699 shares of the company’s stock valued at $320,000 after purchasing an additional 362 shares during the period.

Insider Buying and Selling

In related news, CFO Julia Aijun Wang sold 295 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $158.50, for a total value of $46,757.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Lai Wang sold 458 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $177.32, for a total transaction of $81,212.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Julia Aijun Wang sold 295 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $158.50, for a total transaction of $46,757.50. The disclosure for this sale can be found here. Insiders have sold 14,465 shares of company stock worth $2,229,388 in the last ninety days. 8.90% of the stock is currently owned by corporate insiders.

BeiGene Trading Down 2.9 %

Shares of NASDAQ:BGNE opened at $177.30 on Wednesday. The company has a 50 day moving average of $156.58 and a 200-day moving average of $181.82. The firm has a market cap of $18.33 billion, a P/E ratio of -8.83 and a beta of 0.72. BeiGene, Ltd. has a twelve month low of $118.18 and a twelve month high of $426.56. The company has a current ratio of 5.05, a quick ratio of 4.87 and a debt-to-equity ratio of 0.03.

BeiGene (NASDAQ:BGNEGet Rating) last released its earnings results on Thursday, May 5th. The company reported ($4.24) EPS for the quarter, topping analysts’ consensus estimates of ($4.52) by $0.28. BeiGene had a negative net margin of 218.25% and a negative return on equity of 40.10%. The business had revenue of $306.60 million for the quarter, compared to the consensus estimate of $300.41 million. The firm’s revenue was down 49.4% compared to the same quarter last year. As a group, analysts anticipate that BeiGene, Ltd. will post -15.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BGNE has been the subject of a number of research analyst reports. StockNews.com lowered shares of BeiGene from a “hold” rating to a “sell” rating in a research note on Thursday, June 16th. Morgan Stanley reduced their price target on shares of BeiGene from $300.00 to $293.00 and set an “overweight” rating for the company in a research note on Friday, July 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $300.33.

BeiGene Profile

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Featured Stories

Want to see what other hedge funds are holding BGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeiGene, Ltd. (NASDAQ:BGNEGet Rating).

Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.